Insider Selling: Enfusion, Inc. (NYSE:ENFN) CEO Sells $130,438.28 in Stock

Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan sold 11,452 shares of Enfusion stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $11.39, for a total value of $130,438.28. Following the transaction, the chief executive officer now directly owns 631,847 shares of the company’s stock, valued at approximately $7,196,737.33. The trade was a 1.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Oleg Movchan also recently made the following trade(s):

• On Monday, March 3rd, Oleg Movchan sold 2,790 shares of Enfusion stock. The shares were sold at an average price of $11.48, for a total value of $32,029.20.
• On Tuesday, January 7th, Oleg Movchan sold 2,771 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total value of $28,070.23.

Enfusion Trading Down 0.5 %

Shares of NYSE:ENFN opened at $11.24 on Monday. The stock has a market capitalization of $1.44 billion, a P/E ratio of 280.95, a P/E/G ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a 1-year low of $7.83 and a 1-year high of $11.80. The business has a 50-day moving average price of $10.98 and a two-hundred day moving average price of $9.90.

Enfusion (NYSE:ENFN) last announced its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $52.94 million for the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. As a group, equities analysts predict that Enfusion, Inc. will post 0.06 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Piper Sandler lifted their price objective on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd. Stifel Nicolaus lifted their price target on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Finally, William Blair reissued a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $11.13.

Hedge Funds Weigh In On Enfusion

Several institutional investors have recently modified their holdings of the stock. New York State Common Retirement Fund grew its position in shares of Enfusion by 23.8% during the 4th quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock worth $19,848,000 after buying an additional 370,498 shares during the period. Geode Capital Management LLC grew its position in shares of Enfusion by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 1,050,549 shares of the company’s stock worth $10,823,000 after buying an additional 21,183 shares during the period. Wellington Management Group LLP grew its position in shares of Enfusion by 6.1% during the 4th quarter. Wellington Management Group LLP now owns 1,035,996 shares of the company’s stock worth $10,671,000 after buying an additional 59,700 shares during the period. Azora Capital LP grew its position in shares of Enfusion by 3,255.9% during the 4th quarter. Azora Capital LP now owns 1,000,967 shares of the company’s stock worth $10,310,000 after buying an additional 971,140 shares during the period. Finally, State Street Corp grew its position in shares of Enfusion by 2.3% during the 3rd quarter. State Street Corp now owns 952,895 shares of the company’s stock worth $9,043,000 after buying an additional 21,729 shares during the period. 81.05% of the stock is currently owned by institutional investors and hedge funds.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.